Citius Oncology, Inc.(CTOR)Earnings, Financials & Key Ratios
CTOR•NASDAQ
$0.70
Price updated Jul 2, 2026
AboutCitius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.Show more
- Revenue$0
- EBITDA-$23M-14.2%
- Net Income-$25M-17.1%
- EPS (Diluted)-0.34-13.3%
- ROE-54.42%+7.8%
CTOR Price & Volume
Citius Oncology, Inc. (CTOR) stock price & volume — 10-year historical chart
Loading chart...
Commercial Launch Costs Outpace Revenue Growth Trajectory
Investment Thesis • Updated 2026Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall
Key Thesis Takeaways
- Citius Oncology faces a challenging commercialization phase characterized by erratic revenue generation and an unsustainable SG&A expense profile that reached $27.2 million in 2026Q2.
- The company's reliance on intangible assets, which comprise $71.1 million of its $100.7 million total asset base, introduces significant valuation risk.
- Investors should monitor the firm's ability to bridge its liquidity gap, as the current operating loss of $28.6 million per quarter threatens to exhaust remaining cash reserves.
Verdict Logic
the company's precarious liquidity position, evidenced by a current ratio of 0.50 and a quarterly operating loss of $28.6 million, suggests a high probability of near-term dilutive financing.
CTOR Growth Metrics
Citius Oncology, Inc. (CTOR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-63.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-26.51%
Return on Capital
10 Years-40.66%
5 Years-40.66%
3 Years-45.43%
Last Year-45.62%
CTOR Recent Earnings
Citius Oncology, Inc. (CTOR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (29%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.27-2600.0%
$0.01
Rev
$2M-76.2%
$7M
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$0.06-50.0%
$0.04
Rev
$4M-9.8%
$4M
Q4 2025
Dec 23, 2025Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.08+46.7%
$0.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.27vs $0.01-2600.0% | $2Mvs $7M-76.2% |
| Q1 2026 | Feb 13, 2026 | $0.06vs $0.04-50.0% | $4Mvs $4M-9.8% |
| Q4 2025 | Dec 23, 2025 | $0.06vs $0.06+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.08vs $0.15+46.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Citius Oncology, Inc. (CTOR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.70 | $65.49M | -2.07 | — | — | -54.42% | — | |
| $77.01 | $9.13B | 30.08 | 37.55% | 23.13% | 126.27% | — | |
| $64.39 | $1.26B | -6.62 | -43.89% | -284.18% | -87% | — | |
| $8.61 | $2B | 14.35 | 19.63% | 32.43% | 38.97% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $25.20 | $4.31B | 11.00 | 11.87% | 34.3% | 35.65% | — |
Compare CTOR vs Peers
Citius Oncology, Inc. (CTOR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CTOR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTOR Frequently Asked Questions
Citius Oncology, Inc. (CTOR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Citius Oncology, Inc.'s revenue?
Citius Oncology, Inc. (CTOR) reported $5.6M in revenue for fiscal year 2025.
Is CTOR profitable?
Citius Oncology, Inc. (CTOR) reported a net loss of $42.5M for fiscal year 2025.
Dividend & Returns
What is CTOR's return on equity?
Citius Oncology, Inc. (CTOR) has a return on equity (ROE) of -54.4%. Negative ROE indicates the company is unprofitable.
What is Citius Oncology, Inc.'s free cash flow?
Citius Oncology, Inc. (CTOR) had negative free cash flow of $16.9M in fiscal year 2025, likely due to heavy capital investments.